225Ac-J591 — Investigational Agent
Radiopharmaceutical · Phase 1/2 · Weill Cornell Medicine
Mechanism of Action
An alpha-emitting radioimmunotherapeutic pairing the anti-PSMA monoclonal antibody J591 with actinium-225. Antibody-targeted delivery of high-LET alpha particles produces localized double-strand DNA breaks in PSMA-expressing prostate cancer cells.
Investigational Indications
- Metastatic castration-resistant prostate cancer